Unfractionated heparin dosing nomograms: Road maps to where?

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Weight-adjusted nomograms have been a significant advance in the use of unfractionated heparin (UFH). Clinical trials have demonstrated the ability of weight-adjusted nomograms to achieve a therapeutic activated partial thromboplastin time (aPTT) more rapidly than with standard UFH dosing. Despite this advantage, a significant number of patients have subtherapeutic and supratherapeutic aPTTs. Real-world experiences also corroborate the inability to keep UFH therapeutic with the use of nomograms. Despite the limitations of UFH nomograms, they have been used in several different types of venous and arterial thrombosis treatment settings. Unfortunately, these nomograms are not all consistent and require a considerable amount of time for training health care professionals on their use in order to limit the potential for medication errors. Although UFH nomograms have provided advancement over standard UFH dosing, their limitations still generate the desire for a more predictable anticoagulant.

Original languageEnglish (US)
Pages (from-to)142S-145S
JournalPharmacotherapy
Volume24
Issue number8 II
DOIs
StatePublished - Aug 1 2004

Fingerprint

Nomograms
Heparin
Weights and Measures
Medication Errors
Partial Thromboplastin Time
Therapeutic Uses
Venous Thrombosis
Anticoagulants
Clinical Trials
Delivery of Health Care
Therapeutics

Keywords

  • Activated partial thromboplastin time
  • Nomograms
  • Standard dosing
  • Thrombosis
  • Unfractionated heparin
  • Weight-based dosing

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Unfractionated heparin dosing nomograms : Road maps to where? / Dobesh, Paul P.

In: Pharmacotherapy, Vol. 24, No. 8 II, 01.08.2004, p. 142S-145S.

Research output: Contribution to journalArticle

@article{c115524c5bf04e42bc710d1e21b18acf,
title = "Unfractionated heparin dosing nomograms: Road maps to where?",
abstract = "Weight-adjusted nomograms have been a significant advance in the use of unfractionated heparin (UFH). Clinical trials have demonstrated the ability of weight-adjusted nomograms to achieve a therapeutic activated partial thromboplastin time (aPTT) more rapidly than with standard UFH dosing. Despite this advantage, a significant number of patients have subtherapeutic and supratherapeutic aPTTs. Real-world experiences also corroborate the inability to keep UFH therapeutic with the use of nomograms. Despite the limitations of UFH nomograms, they have been used in several different types of venous and arterial thrombosis treatment settings. Unfortunately, these nomograms are not all consistent and require a considerable amount of time for training health care professionals on their use in order to limit the potential for medication errors. Although UFH nomograms have provided advancement over standard UFH dosing, their limitations still generate the desire for a more predictable anticoagulant.",
keywords = "Activated partial thromboplastin time, Nomograms, Standard dosing, Thrombosis, Unfractionated heparin, Weight-based dosing",
author = "Dobesh, {Paul P.}",
year = "2004",
month = "8",
day = "1",
doi = "10.1592/phco.24.12.142S.36113",
language = "English (US)",
volume = "24",
pages = "142S--145S",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "8 II",

}

TY - JOUR

T1 - Unfractionated heparin dosing nomograms

T2 - Road maps to where?

AU - Dobesh, Paul P.

PY - 2004/8/1

Y1 - 2004/8/1

N2 - Weight-adjusted nomograms have been a significant advance in the use of unfractionated heparin (UFH). Clinical trials have demonstrated the ability of weight-adjusted nomograms to achieve a therapeutic activated partial thromboplastin time (aPTT) more rapidly than with standard UFH dosing. Despite this advantage, a significant number of patients have subtherapeutic and supratherapeutic aPTTs. Real-world experiences also corroborate the inability to keep UFH therapeutic with the use of nomograms. Despite the limitations of UFH nomograms, they have been used in several different types of venous and arterial thrombosis treatment settings. Unfortunately, these nomograms are not all consistent and require a considerable amount of time for training health care professionals on their use in order to limit the potential for medication errors. Although UFH nomograms have provided advancement over standard UFH dosing, their limitations still generate the desire for a more predictable anticoagulant.

AB - Weight-adjusted nomograms have been a significant advance in the use of unfractionated heparin (UFH). Clinical trials have demonstrated the ability of weight-adjusted nomograms to achieve a therapeutic activated partial thromboplastin time (aPTT) more rapidly than with standard UFH dosing. Despite this advantage, a significant number of patients have subtherapeutic and supratherapeutic aPTTs. Real-world experiences also corroborate the inability to keep UFH therapeutic with the use of nomograms. Despite the limitations of UFH nomograms, they have been used in several different types of venous and arterial thrombosis treatment settings. Unfortunately, these nomograms are not all consistent and require a considerable amount of time for training health care professionals on their use in order to limit the potential for medication errors. Although UFH nomograms have provided advancement over standard UFH dosing, their limitations still generate the desire for a more predictable anticoagulant.

KW - Activated partial thromboplastin time

KW - Nomograms

KW - Standard dosing

KW - Thrombosis

KW - Unfractionated heparin

KW - Weight-based dosing

UR - http://www.scopus.com/inward/record.url?scp=3543081470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3543081470&partnerID=8YFLogxK

U2 - 10.1592/phco.24.12.142S.36113

DO - 10.1592/phco.24.12.142S.36113

M3 - Article

C2 - 15334860

AN - SCOPUS:3543081470

VL - 24

SP - 142S-145S

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 8 II

ER -